Latest News - Ortho Dermatologics

Friday, May 11, 2018

Valeant is Becoming Bausch Health Companies, Inc.

Bausch Health Companies, Inc. will become the new name of Valeant Pharmaceuticals International, Inc., effective in July 2018. Based on the strong brand equity of the company’s businesses a…

Read the full story

Monday, April 09, 2018

Ortho Dermatologics’ DUOBRII Improves Psoriasis Symptoms As Early As Two Weeks

DUOBRII (halobetasol propionate and tazarotene) (IDP-118) lotion demonstrated significant superiority over vehicle as early as two weeks, according to new research in Journal of the American Academy o…

Read the full story

Thursday, March 01, 2018

Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2018 Aspire Higher Scholarship Program

Ortho Dermatologics is accepting applications for the 2018 Aspire Higher scholarship program for students who have been affected by dermatologic conditions. Through the program, nine students will …

Read the full story

Friday, February 16, 2018

Ortho Dermatologics Presents Analysis of Siliq Phase 3 Data on Disease-Related Anxiety and Depression in Patients with Psoriasis

Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC, shared the results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities …

Read the full story

Wednesday, February 14, 2018

FDA Accepts Ortho Dermatologics' NDA For Jemdel Plaque Psoriasis Treatment

The FDA has accepted the New Drug Application for Jemdel (halobetasol propionate 0.01%) (IDP-122) lotion from Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. If approved…

Read the full story

Monday, January 22, 2018

Retin-A Micro Gel Microsphere 0.06% Now Available from Ortho Dermatologics to Treat Acne

Retin-A Micro (tretinoin) gel microsphere 0.06% is now available commercially to healthcare professionals. The FDA approved Ortho Dermatologics' Supplemental New Drug Application (sNDA) for Retin-…

Read the full story

Friday, January 12, 2018

FDA Accepts Ortho Dermatologics' Filing for IDP-121 Acne Treatment In Lotion Form

The FDA has accepted  Ortho Dermatologics' New Drug Application for IDP-121 (tretinoin 0.05%) lotion (Altreno) with a PDUFA action date of Aug. 27, 2018. If approved, Altreno will be the firs…

Read the full story